RXST
RxSight, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeRxSight reported Q3 2026 revenue of $24.6M, down 19% YoY, with LAL procedure volume declining 11% due to competitive pressures and internal sales-force restructuring that disrupted customer engagement. While the $60M upfront Alcon collaboration provides strategic optionality, near-term outlook remains unclear with no formal 2026 guidance and Q4 expected only in line with Q2 levels. Analyst consensus shifted sharply negative, with Wells Fargo cutting its price target 33% to $6.00 and Needham cutting from $11 to $7.
Red flags
- •Revenue declined 19% YoY in Q3 2026, driven by competitive pressures
- •LAL procedure volume down 11% YoY to 23,128 units
- •Major sales-force restructuring and territory remapping causing near-term customer engagement disruption
- •Management withdrew formal 2026 full-year guidance
- •Q4 expected flat to down sequentially ('in line with Q2'), implying weak finish to year
- •Three major brokerages cut price targets in early November (Wells Fargo -33%, Needham -36%, Piper Sandler -20%)
- •Alcon collaboration revenue contribution minimal in Q3, limiting near-term revenue offset
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).